<DOC>
	<DOC>NCT00640588</DOC>
	<brief_summary>This study will explore HBV kinetics in CHB patients during the first 24 weeks of treatment with telbivudine</brief_summary>
	<brief_title>Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Male or female, at least 18 years of age. Documented compensated HBeAg negative CHB defined by baseline HBV serology, DNA and ALT criteria. Coinfection with HCV, HDV, or HIV. Prior therapy with nucleos(t)ides in NA√èVE patient and prior treatment with lamivudine in patients with suboptimal response to adefovir. History of hepatic decompensation History of malignancy Patient has one or more additional known primary or secondary causes of liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis B, chronic</keyword>
	<keyword>Viral kinetics</keyword>
	<keyword>Telbivudine</keyword>
	<keyword>Adefovir</keyword>
	<keyword>Compliance</keyword>
</DOC>